Skip to content

Contribution of Ondansetron to Preventing Post-Dural Puncture Headaches Following Spinal Anesthesia

Contribution of Ondansetron to Preventing Post-Dural Puncture Headaches Following Spinal Anesthesia for Cesarean Sections : A Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06444737
Acronym
OPDPH
Enrollment
300
Registered
2024-06-06
Start date
2023-11-30
Completion date
2024-08-30
Last updated
2024-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-Dural Puncture Headache

Brief summary

A prospective, bicentric, randomized, double-blind controlled study including parturients scheduled for elective caesarean delivery under spinal anaesthesia and randomized and assigned to one of the two groups: Group O ondansetron : receiving Intravenous (IV) ondansetron 0.10 mg/ kg diluted in 5 ml normal saline, 5 min before spinal anesthesia Group C control : receiving IV normal saline 5 ml (control group) 5 min before spinal anesthesia OBJECTIVE : To evaluate the efficacy of ondansetron in preventing post-dural puncture headache after spinal anaesthesia for caesarean section.

Detailed description

Spinal anesthesia is the most common anesthetic technique used for Caesarean sections. However, it is not denied from complications. Post-dural puncture headache is a major complication of spinal anesthesia, with an incidence ranging from 1.5% to 36%. OBJECTIVE : To evaluate the efficacy of ondansetron in preventing post-dural puncture headache after spinal anaesthesia for caesarean section. the investigators conducted a prospective, bicentric, randomized, double-blind controlled study over a period of 07 months from November 2023 to june 2024. the investigators included in the study all parturients: * Aged between 18-45 years * ASA 2 * Between 37 and 41 weeks of gestation * scheduled for elective caesarean delivery under spinal anaesthesia * To be delivered by unscheduled caesarean section whose indication does not involve a vital maternal or fetal emergency, according to the Lucas' classification. The eligible parturients were randomly assigned to two groups through block randomization using computerized random numbers. were assigned to one of the two parallel groups to receive either : * Intravenous (IV) ondansetron 0.10 mg/ kg diluted in 5 ml normal saline, 5 min before spinal anesthesia : Group O (Ondansetron) * Or IV normal saline 5 ml (control group) 5 min before spinal anesthesia : Group C (control)

Interventions

Intravenous normal saline 5 ml (control group) 5 min before spinal anesthesia

Intravenous (IV) ondansetron 0.10 mg/ kg diluted in 5 ml normal saline, 5 min before spinal anesthesia

Sponsors

Mongi Slim Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Aged between 18-45 years * ASA 2 * Between 37 and 41 weeks of gestation * scheduled for elective caesarean delivery under spinal anaesthesia * To be delivered by unscheduled caesarean section whose indication does not involve a vital maternal or fetal emergency, according to the Lucas' classification

Exclusion criteria

* All patients who required : * more than two attempts for spinal anaesthesia * conversion to general anesthesia following failure of spinal anesthesia (defined as a sensory block level \<T6) or an intraoperative complication (such as hemorrhage or anaphylactic shock). As well as patients who have subsequently withdrawn their consent for participating to our study.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of post-dural punction headache (PDPH) during the first seven postoperative days.7 daysthe occurrence of positional headaches at any time postoperatively

Secondary

MeasureTime frameDescription
day of PDPH's resolution7 dayson postoperatively
Headache severity7 daysassessed by the numerical pain scale from 0 to 10 (0 being no pain and 10 being the maximum unimaginable pain).
Need for analgesic treatment due to headaches7 daysparacetamol or NSAIDs
day of PDPH's occurence7 dayson postoperatively
Mean arterial pressure in mmgh3 daysMean arterial pressure during hospitalization
heart rate3 daysMean arterial pressure during hospitalization
Occurrence of post-operative nausea and/or vomiting7 daysneed of treatement

Countries

Tunisia

Contacts

Primary ContactMhamed Sami Mebazaa, professor
msmebazaa@gmail.com22252589
Backup ContactAmani Ben Haj Youssef, assistant
amanibhy@hotmail.fr96874336

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026